These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22605655)

  • 41. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis.
    Brandse JF; Bennink RJ; van Eeden S; Löwenberg M; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2016 Jun; 22(6):1384-90. PubMed ID: 26978724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
    Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.
    Yarlas A; Willian MK; Nag A
    Qual Life Res; 2021 Jul; 30(7):1925-1938. PubMed ID: 33651279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.
    Jiang XL; Wang HH; Cui HF
    Med Sci Monit; 2015 Jan; 21():163-70. PubMed ID: 25582578
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.
    Haberman Y; Karns R; Dexheimer PJ; Schirmer M; Somekh J; Jurickova I; Braun T; Novak E; Bauman L; Collins MH; Mo A; Rosen MJ; Bonkowski E; Gotman N; Marquis A; Nistel M; Rufo PA; Baker SS; Sauer CG; Markowitz J; Pfefferkorn MD; Rosh JR; Boyle BM; Mack DR; Baldassano RN; Shah S; Leleiko NS; Heyman MB; Grifiths AM; Patel AS; Noe JD; Aronow BJ; Kugathasan S; Walters TD; Gibson G; Thomas SD; Mollen K; Shen-Orr S; Huttenhower C; Xavier RJ; Hyams JS; Denson LA
    Nat Commun; 2019 Jan; 10(1):38. PubMed ID: 30604764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
    Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP
    Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
    Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
    Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.
    Kuznetsov NV; Zargari A; Gielen AW; von Stein OD; Musch E; Befrits R; Lofberg R; von Stein P
    BMC Gastroenterol; 2014 Apr; 14():79. PubMed ID: 24758565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis.
    Tursi A; Elisei W; Giorgetti G; Aiello F; Brandimarte G
    Minerva Gastroenterol Dietol; 2011 Sep; 57(3):247-55. PubMed ID: 21769075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis.
    Arai Y; Arihiro S; Matsuura T; Kato T; Matsuoka M; Saruta M; Mitsunaga M; Matsuura M; Fujiwara M; Okayasu I; Ito S; Tajiri H
    Inflamm Bowel Dis; 2014 Jul; 20(7):1208-16. PubMed ID: 24846719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation.
    Suzuki Y; Uchiyama K; Kato M; Matsuo K; Nakagawa T; Kishikawa H; Kimura N; Kasanuki J; Ino S
    J Clin Gastroenterol; 2015; 49(5):401-6. PubMed ID: 25127112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.
    Ardizzone S; Maconi G; Russo A; Imbesi V; Colombo E; Bianchi Porro G
    Gut; 2006 Jan; 55(1):47-53. PubMed ID: 15972298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.